Rani-Logo.jpg
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
November 14, 2024 08:00 ET | Rani Therapeutics, LLC
- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting...
LXP.png
LXP Industrial Trust to Report Third Quarter 2024 Results and Host Conference Call November 6, 2024
October 08, 2024 07:00 ET | LXP Industrial Trust
WEST PALM BEACH, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LXP Industrial Trust (NYSE: LXP) (“LXP”), a real estate investment trust (REIT) focused on Class A warehouse and distribution real estate...
Progress_logo.jpg
Progress Announces Third Quarter 2024 Financial Results
September 24, 2024 16:15 ET | Progress Software Corporation
Progress announces third quarter financial earnings for fiscal year 2024
Adalimumab 11mg via RaniPill HC vs Adalimumab Biosimilar 5mg via Subcutaneous Injection
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
November 08, 2023 16:05 ET | Rani Therapeutics, LLC
- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of...
Rani-Logo.jpg
Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results
November 01, 2023 16:05 ET | Rani Therapeutics, LLC
- Cash runway extended into 2025 - - Cash runway expected to extend beyond topline results from Phase 2 trial for RT-102, topline results from Phase 1 trial for RT-111, and development of...